- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06330181
Terapia de caminhada virtual para dor neuropática após lesão incompleta da medula espinhal
The purpose of this study is to determine if playing a virtual reality walking game can help improve neuropathic pain in adults with incomplete spinal cord injury.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Many people with SCI experience neuropathic pain. Neuropathic pain is often described as sharp, burning, or electric. 'Traditional' treatments often do not do a good job of reducing neuropathic pain. Therefore, it is important to see if 'non-traditional' treatments might work. Scientists think that neuropathic pain occurs in SCI because the sensations coming from the eyes and up the spinal cord to the brain do not match what the brain thinks it told the body to do. This 'mismatch' may result in changes in the brain that make neuropathic pain possible. Virtual reality walking may potentially reduce this 'mismatch' by creating the 'illusion' that the person is walking. The brain then thinks it is telling the body to walk AND the information coming from the eyes matches its instructions. This 'matching' may reverse the brain changes that make neuropathic pain possible. The current study is specifically focused on individuals whose SCI has been classified as incomplete (ASIA B, C, or D).
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Ami Lisenbee
- Número de telefone: 804-569-5965
- E-mail: sci@vrwalk.org
Locais de estudo
-
-
Texas
-
College Station, Texas, Estados Unidos, 77843
- Recrutamento
- Texas A&M University
-
Investigador principal:
- Zina Trost, PhD
-
Contato:
- Ami Lisenbee
- Número de telefone: 804-569-5965
- E-mail: sci@vrwalk.org
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
The study will recruit individuals with incomplete injury (American Spinal Injury Association [ASIA] classification B, C, or D) with lumbar, paraplegic, or low tetraplegic (C5-C7) injury. Additional criteria will include:
- Must have persistent NP symptoms that are of daily severity of at least 4/10 for 3 or more months
- Must endorse more than 2 items on a 7-item Spinal Cord Injury Pain Instrument, SCIPI
- Must be 18 years of age or older
- Must be more than one and a half years post-injury to begin study (can be screened at an earlier time for eligibility)
- Must have mobile connectivity with usable service
- Must be stable on pain medication for 1 or more months
- Must be cleared on the VRWalk physical activity clearance scale
- Must not have motion sickness that interferes with daily life
- Must use a wheelchair at least 75% of the time
Exclusion Criteria:
- Individuals with Injury levels between C1 and C4
- Individuals under the age of 18
- Individuals who were injured within the past year
- Individuals who cannot comprehend spoken English
- Individuals who are in prison
- Individuals who are blind
- Individuals who experience severe motion sickness
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Virtual reality (VR) game 1
Participants will be asked to play a virtual reality game twice a day for 10 days. |
Individuals playing VR game 1 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective. Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart |
|
Comparador Ativo: Virtual reality (VR) game 2
Participants will be asked to play a virtual reality game twice a day for 10 days. |
Individuals playing VR game 2 will wear a head-mounted display to allow them to visualize virtual legs in the virtual environment. When wearing the display, individuals will see the legs and arms of their virtual avatar from a first-person perspective. Individuals will engage in virtual reality sessions in their home twice daily over the course of 10 days in a two-week period. Each daily session will take approximately 30 minutes, with 5-10 minutes dedicated to the virtual walking experience. Additionally, each daily session will be scheduled a minimum of 4 hours apart. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Pain Intensity
Prazo: Baseline - final follow up (up to 18 months)
|
The Numeric Rating Scale (NRS) measures pain intensity via a 0-10 numeric rating scale 0-10 where 0 is no pain, and 10 is the worst pain imaginable. |
Baseline - final follow up (up to 18 months)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Pain Quality
Prazo: Baseline - final follow up (up to 18 months)
|
The Neuropathic Pain Scale (NPS) assesses the distinct pain qualities, including sharpness, heat/cold, dullness, intensity, overall unpleasantness, and surface vs. deep pain. The NPS consists of 10 items. 0 equals 'No sensation' and 10 equals 'Worst sensation imaginable.' All the items are rated 0-10 scale, with a higher score indicative of more neuropathic pain for each type of respective pain. |
Baseline - final follow up (up to 18 months)
|
|
Change in Pain Interference
Prazo: Baseline - final follow up (up to 18 months)
|
The International Spinal Cord Injury Pain Basic Data Set version 2.0 interference assesses the degree to which pain interferes with day-to-day activities, mood, and sleep. Items are scored on a 0-10 numeric rating scale, and scores are summed to yield an interference score ranging from 0 to 30. Higher scores indicate greater interference from pain. |
Baseline - final follow up (up to 18 months)
|
|
Post treatment change
Prazo: at follow up (up to 18 months)
|
The Patient Global Impression of Change is a one item 7 point Likert item assessing improvement of the participants' overall status. A score of 1 is 'Very Much Improved', and a score of 7 is 'Very Much Worse.' Higher scores indicate less perceived improvement. Range of scores: 1-7 |
at follow up (up to 18 months)
|
|
Change in mood
Prazo: Baseline - final follow up (up to 18 months)
|
Mood will be assessed using the Patient Health Questionnaire-9. Participants will be asked to rate how often they have been bothered by specific problems on a 4-point Likert scale, where 0 is 'Not at all,' and 3 is 'Nearly every day.' The items are summed to yield a score ranging from 0-27. Higher scores indicate worse mood. |
Baseline - final follow up (up to 18 months)
|
|
Change in quality of life
Prazo: Baseline - final follow up (up to 18 months)
|
Quality of life is assessed by the Satisfaction with Life Scale. This is a 5 item survey. Response options are a 7-point Likert scale where 1 is 'Strongly disagree,' and 7 is 'Strongly agree'. Items may be assessed individually or by summing items. Range of scores: 5-35. Higher scores indicate more satisfaction in life |
Baseline - final follow up (up to 18 months)
|
|
Neurological changes
Prazo: Baseline - 6 months
|
For eligible and interested participants, functional Magnetic Resonance Imaging (fMRI) will be used to observe neurological changes. Pre and post-study images will be compared by experienced researchers. |
Baseline - 6 months
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do Sistema Nervoso
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Dor
- Manifestações Neurológicas
- Ferimentos e Lesões
- Neuralgia
- Doenças do Sistema Nervoso Periférico
- Lesões da Medula Espinhal
- Doenças do Sistema Nervoso Central
- Doenças Neuromusculares
- Doenças da Medula Espinhal
- Trauma, Sistema Nervoso
Outros números de identificação do estudo
- SC220178
- SC220178 (Número de outro subsídio/financiamento: Congressionally Directed Medical Research Programs)
- HT9425-23-1-1019 (Número de outro subsídio/financiamento: Department of Depense)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .